The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

Moderna (MRNA) ended the recent trading session at $27.54, demonstrating a +2.53% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.8%.

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

Ribosomes are tiny molecular machines inside all living cells that build proteins, and ribosome biogenesis is the complex, ...

Researchers use targeted lipid nanoparticles loaded with mRNA to reprogram T cells to fight autoimmune diseases ...

As a new variant that causes 'razor blade throat' spreads, the FDA updates vaccine warnings to include information on heart ...

A more effective vaccine technology may be on the horizon. In a new study in mice, researchers from the University of ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

Moderna (MRNA) Outperforms Broader Market: What You Need to Know. In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.